Youth-Onset Type 2 Diabetes in the Incretin Era: Aggressive Biology, Expanding Therapeutics, and Unresolved Evidence Gaps

Youth-onset type 2 diabetes (Y-T2D) is a heterogeneous cardiometabolic disease in which pubertal insulin resistance, limited β-cell reserve, obesity-related metabolic dysfunction, genetic susceptibility, early-life exposures, and barriers to care converge. This structured narrative review synthesizes evidence from pediatric randomized trials, longitudinal cohorts, clinical guidelines, and studies of metabolic bariatric surgery in adolescents identified through database searches updated to 15 October 2026. Pediatric evidence shows limited durability of metformin-based therapy in the selected TODAY population and continued β-cell deterioration in RISE, which included youth with impaired glucose tolerance and those with recently diagnosed type 2 diabetes. Contemporary trials demonstrate clinically important short-term glycemic efficacy for GLP-1 receptor agonists, SGLT2 inhibitors, and tirzepatide; among pediatric type 2 diabetes trials, only tirzepatide has produced a large concurrent reduction in BMI. However, differences in baseline HbA1c, background therapy, trial duration, estimands, and rescue-treatment rules preclude indirect efficacy rankings. Long-term effects on β-cell preservation, growth, puberty, bone and reproductive health, and cardiovascular or kidney outcomes remain unproven. Clinical priorities therefore include accurate classification, prompt treatment intensification, obesity-directed care, complication surveillance from diagnosis, and active mitigation of psychosocial and access barriers. This review provides an evidence-tiered interpretation of disease biology and a practical treatment-sequencing framework that distinguishes established pediatric findings from adult or experimental extrapolation.